title: Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): antibiotics stimulate lytic phage activity.
abstract: The Burkholderia cepacia complex (Bcc) is a group of at least 18 species of Gram-negative opportunistic pathogens that can cause chronic lung infection in cystic fibrosis (CF) patients. Bcc organisms possess high levels of innate antimicrobial resistance, and alternative therapeutic strategies are urgently needed. One proposed alternative treatment is phage therapy, the therapeutic application of bacterial viruses (or bacteriophages). Recently, some phages have been observed to form larger plaques in the presence of sublethal concentrations of certain antibiotics; this effect has been termed phage-antibiotic synergy (PAS). Those reports suggest that some antibiotics stimulate increased production of phages under certain conditions. The aim of this study is to examine PAS in phages that infect Burkholderia cenocepacia strains C6433 and K56-2. Bcc phages KS12 and KS14 were tested for PAS, using 6 antibiotics representing 4 different drug classes. Of the antibiotics tested, the most pronounced effects were observed for meropenem, ciprofloxacin, and tetracycline. When grown with subinhibitory concentrations of these three antibiotics, cells developed a chain-like arrangement, an elongated morphology, and a clustered arrangement, respectively. When treated with progressively higher antibiotic concentrations, both the sizes of plaques and phage titers increased, up to a maximum. B. cenocepacia K56-2-infected Galleria mellonella larvae treated with phage KS12 and low-dose meropenem demonstrated increased survival over controls treated with KS12 or antibiotic alone. These results suggest that antibiotics can be combined with phages to stimulate increased phage production and/or activity and thus improve the efficacy of bacterial killing.
authors.affiliation: Centennial Centre for Interdisciplinary Science, Department of Biological Sciences, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Fatima
authors.initials: F
authors.lastname: Kamal
authors.affiliation: Centennial Centre for Interdisciplinary Science, Department of Biological Sciences, University of Alberta, Edmonton, Alberta, Canada jon.dennis@ualberta.ca.
authors.forename: Jonathan J
authors.initials: JJ
authors.lastname: Dennis
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001435:Bacteriophages / Q000254:growth & development*; D001688:Biological Products / Q000494:pharmacology*; D042602:Burkholderia cepacia complex / Q000187:drug effects* / Q000648:ultrastructure / Q000821:virology*; D015169:Colony Count, Microbial; D004357:Drug Synergism; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects*; D046529:Microscopy, Electron, Transmission; D010948:Viral Plaque Assay
chemical_list: D000900:Anti-Bacterial Agents; D001688:Biological Products